| meta-analysis | Q815382 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1002/ART.21539 |
| P698 | PubMed publication ID | 16385548 |
| P50 | author | John Ioannidis | Q6251482 |
| Andrea Doria | Q38544117 | ||
| Antonella Maria Vittoria Afeltra | Q67891878 | ||
| Athanasios George Tzioufas | Q92673448 | ||
| P2093 | author name string | Filip De Keyser | |
| Loreto Massardo | |||
| Murat Inanc | |||
| Alessandro Mathieu | |||
| Mauro Galeazzi | |||
| Chi Chiu Mok | |||
| Shunsei Hirohata | |||
| Deh-Ming Chang | |||
| Gabriella Morozzi | |||
| Ales Ambrozic | |||
| Giovanni Sanna | |||
| Taku Yoshio | |||
| Ilse E A Hoffman | |||
| Alberto J Spindler | |||
| Fotini B Karassa | |||
| P433 | issue | 1 | |
| P921 | main subject | meta-analysis | Q815382 |
| neuropsychiatric systemic lupus erythematosus | Q9358981 | ||
| P304 | page(s) | 312-324 | |
| P577 | publication date | 2006-01-01 | |
| P1433 | published in | Arthritis and Rheumatism | Q23929027 |
| P1476 | title | Accuracy of anti-ribosomal P protein antibody testing for the diagnosis of neuropsychiatric systemic lupus erythematosus: an international meta-analysis | |
| P478 | volume | 54 |
| Q37548266 | Accuracy of cerebrospinal fluid IL-6 testing for diagnosis of lupus psychosis. A multicenter retrospective study |
| Q80625606 | Acute psychosis in systemic lupus erythematosus |
| Q26996498 | Anti-NR2A/B Antibodies and Other Major Molecular Mechanisms in the Pathogenesis of Cognitive Dysfunction in Systemic Lupus Erythematosus |
| Q37498220 | Anti-ribosomal P antibodies related to depression in early clinical course of systemic lupus erythematosus |
| Q38218308 | Anti-ribosomal-P antibodies in lupus nephritis, neuropsychiatric lupus, lupus hepatitis, and Chagas' disease: promising yet limited in clinical utility |
| Q80753084 | Antibodies directed against ribosomal P proteins cross-react with phospholipids |
| Q36294377 | Antiribosomal-P autoantibodies from psychiatric lupus target a novel neuronal surface protein causing calcium influx and apoptosis. |
| Q36787722 | Are anti-ribosomal P protein antibodies relevant in systemic lupus erythematosus? |
| Q46951550 | Association of anti-ribosomal P protein antibodies with neuropsychiatric and other manifestations of systemic lupus erythematosus. |
| Q34947235 | Association of antiphosphatidylserine/prothrombin antibodies with neuropsychiatric systemic lupus erythematosus |
| Q36392326 | Association of cerebrospinal fluid anti-ribosomal p protein antibodies with diffuse psychiatric/neuropsychological syndromes in systemic lupus erythematosus |
| Q35673044 | Autoantibodies Affect Brain Density Reduction in Nonneuropsychiatric Systemic Lupus Erythematosus Patients. |
| Q36307423 | Autoantibodies and neuropsychiatric events at the time of systemic lupus erythematosus diagnosis: results from an international inception cohort study |
| Q36332517 | Autoantibodies as biomarkers for the prediction of neuropsychiatric events in systemic lupus erythematosus |
| Q90338344 | Autoantibodies associated with neuropsychiatric systemic lupus erythematosus: the quest for symptom-specific biomarkers |
| Q56806670 | Autoantibodies in SLE: Specificities, Isotypes and Receptors |
| Q38222127 | Autoantibodies involved in neuropsychiatric manifestations associated with systemic lupus erythematosus: a systematic review |
| Q37926164 | Autoimmune and inflammatory mechanisms of CNS damage |
| Q47657635 | Brain magnetic resonance imaging, cerebrospinal fluid, and autoantibody profile in 118 patients with neuropsychiatric lupus. |
| Q35458567 | Brain-reactive antibodies and disease. |
| Q36766114 | Classification criteria for neuropsychiatric systemic lupus erythematosus: do they need a discussion? |
| Q49562027 | Clinical Factors Associated with Brain Volume Reduction in Systemic Lupus Erythematosus Patients without Major Neuropsychiatric Manifestations |
| Q26773164 | Clinical Features of Neuropsychiatric Syndromes in Systemic Lupus Erythematosus and Other Connective Tissue Diseases |
| Q37412463 | Clinical interpretation of antinuclear antibody tests in systemic rheumatic diseases. |
| Q48961470 | Common mental disorders and psychological distress in systemic lupus erythematosus are not associated with disease activity |
| Q82879302 | Correlation between enzyme immunoassay and indirect immunofluorescence test for high titer of anti-ribosomal-P antibodies |
| Q84601242 | Deciphering the association of anti P ribosomal antibodies and neuropsychiatric affection in systemic lupus erythematosus |
| Q38186995 | Diagnosis and management of neuropsychiatric SLE. |
| Q35620320 | Diagnostic value and clinical laboratory associations of antibodies against recombinant ribosomal P0, P1 and P2 proteins and their native heterocomplex in a Caucasian cohort with systemic lupus erythematosus |
| Q90415013 | Flares in systemic lupus erythematosus: diagnosis, risk factors and preventive strategies |
| Q33723529 | Glutamate receptor biology and its clinical significance in neuropsychiatric systemic lupus erythematosus |
| Q35225108 | Human lupus autoantibodies against NMDA receptors mediate cognitive impairment. |
| Q60046879 | Laboratory and Neuroimaging Biomarkers in Neuropsychiatric Systemic Lupus Erythematosus: Where Do We Stand, Where To Go? |
| Q33383647 | Limited reliability of the indirect immunofluorescence technique for the detection of anti-Rib-P antibodies |
| Q28268802 | Lupus brain fog: a biologic perspective on cognitive impairment, depression, and fatigue in systemic lupus erythematosus |
| Q82794448 | Multi-center evaluation of autoantibodies to the major ribosomal P C22 epitope |
| Q55267080 | Neurological Disease in Lupus: Toward a Personalized Medicine Approach. |
| Q92886214 | Neuroprotective effect of microglia against impairments of auditory steady-state response induced by anti-P IgG from SLE patients in naïve mice |
| Q36440223 | Neuropsychiatric features of a cohort of patients with systemic lupus erythematosus |
| Q93578153 | Neuropsychiatric lupus |
| Q37922765 | Neuropsychiatric manifestations in systemic lupus erythematosus: epidemiology, pathophysiology and management |
| Q59924786 | Neuropsychiatric systemic lupus erythematosus |
| Q38247180 | Neuropsychiatric systemic lupus erythematosus: pathogenesis and biomarkers |
| Q47136259 | Nitrated nucleosome levels and neuropsychiatric events in systemic lupus erythematosus; a multi-center retrospective case-control study |
| Q33574487 | Pathogenesis, diagnosis and management of neuropsychiatric SLE manifestations |
| Q36222405 | Predictive value of antinuclear antibodies in autoimmune diseases classified by clinical criteria: Analytical study in a specialized health institute, one year follow-up |
| Q33396284 | Primary antiphospholipid antibody syndrome presenting with encephalopathy, psychosis and seizures |
| Q58093032 | Psychosis in Systemic Lupus Erythematosus |
| Q33882185 | Ribosomal P autoantibodies are present before SLE onset and are directed against non-C-terminal peptides |
| Q27023280 | Serology of Lupus Erythematosus: Correlation between Immunopathological Features and Clinical Aspects |
| Q86096678 | Significance of antibodies against the native ribosomal P protein complex and recombinant P0, P1, and P2 proteins in the diagnosis of Chinese patients with systemic lupus erythematosus |
| Q37930475 | Systemic lupus erythematosus, the brain, and anti-NR2 antibodies |
| Q34913499 | The Emerging Link Between Autoimmune Disorders and Neuropsychiatric Disease |
| Q39253402 | The blood brain barrier and neuropsychiatric lupus: new perspectives in light of advances in understanding the neuroimmune interface |
| Q38889566 | The role of B cells and autoantibodies in neuropsychiatric lupus |
| Q27005906 | Unmet medical needs in systemic lupus erythematosus |
Search more.